TABLE 1.
Study cohort characteristics
| Entire cohort | Patients with hematologic malignancies | Comparison group | p | |
|---|---|---|---|---|
| N (%) | 423 | 315 (74.5) | 108 (25.5) | |
| Age (median [IQR]) | 70 (61–77) | 71 (61–78) | 69 (58–74) | 0.062 |
| Gender, male (N [%]) | 223 (53) | 176 (56) | 47 (44) | 0.026 |
| Comorbidities (N [%]) | ||||
| Cardiac | 58 (14) | 43 (14) | 15 (14) | 0.951 |
| Hypertension | 131 (31) | 97 (31) | 34 (32) | 0.854 |
| Diabetes mellitus | 80 (19) | 58 (18) | 22 (20) | 0.654 |
| Lung | 24 (6) | 20 (6) | 4 (4) | 0.305 |
| Renal | 13 (3) | 13 (4) | 0 | 0.046 |
| Obesity | 36 (9) | 25 (8) | 11 (10) | 0.47 |
| Autoimmune | 11 (3) | 8 (3) | 3 (3) | > 0.999 |
| Other cancer | 34 (8) | 25 (8) | 9 (8) | 0.896 |
| Post‐vaccination COVID19 serology | ||||
| Positive, ≥ 12 AU/ml (N [%]) | 342 (81) | 235 (75) | 107 (99) | < 0.001 |
| Negative, < 12 AU/ml (N [%]) | 81 (19) | 80 (25) | 1 (1) | |
| Antibody titer (AU) (median [IQR]) | 118 (30–186) | 85 (11–172) | 157 (130–221) | < 0.001 |
| Time from vaccine to serology essay (days) (median [IQR]) | 32 (28–39) | 32 (29–40) | 33.5 (28–39) | 0.61 |
| Matched analysis (N) | 69 | 69 | ||
| Seropositive, ≥ 12 AU/ml (N [%]) | 52 (75) | 68 (99) | < 0.001 | |
| Seronegative, < 12 AU/ml (N [%]) | 17 (25) | 1 (1) | ||
| Antibodies titer (AU) (median [IQR]) | 90 (12–185) | 173 (133–232) | < 0.001 |